ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $54,229,402 | -39.0% | 2,703,360 | -14.3% | 0.00% | -40.0% |
Q2 2023 | $88,943,704 | +82.6% | 3,152,914 | +11.3% | 0.01% | +66.7% |
Q1 2023 | $48,710,796 | -60.8% | 2,832,023 | -54.1% | 0.00% | -25.0% |
Q4 2022 | $124,229,038 | +101.2% | 6,168,274 | +116.4% | 0.00% | 0.0% |
Q3 2022 | $61,735,000 | -29.6% | 2,850,174 | -8.6% | 0.00% | -20.0% |
Q2 2022 | $87,665,000 | -8.7% | 3,119,734 | +50.0% | 0.01% | 0.0% |
Q1 2022 | $95,992,000 | -15.2% | 2,080,440 | +54.5% | 0.01% | 0.0% |
Q4 2021 | $113,180,000 | +31.4% | 1,346,416 | +4.2% | 0.01% | 0.0% |
Q3 2021 | $86,116,000 | +20.9% | 1,292,263 | -3.5% | 0.01% | +25.0% |
Q2 2021 | $71,253,000 | +11.8% | 1,339,340 | -8.8% | 0.00% | 0.0% |
Q1 2021 | $63,748,000 | +37.7% | 1,469,191 | +64.8% | 0.00% | +33.3% |
Q4 2020 | $46,305,000 | +776.5% | 891,509 | +451.7% | 0.00% | – |
Q3 2020 | $5,283,000 | -19.9% | 161,594 | +17.7% | 0.00% | – |
Q2 2020 | $6,592,000 | – | 137,270 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 1,824,583 | $39,520,000 | 14.33% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,301,771 | $49,857,000 | 4.79% |
Matrix Capital Management Company, LP | 9,199,973 | $199,271,000 | 3.81% |
Integral Health Asset Management, LLC | 550,000 | $11,913,000 | 2.31% |
Avidity Partners Management LP | 4,223,100 | $91,472,000 | 1.86% |
Affinity Asset Advisors, LLC | 170,000 | $3,682,000 | 1.03% |
Eventide Asset Management | 1,861,000 | $40,309,000 | 0.79% |
Sofinnova Investments, Inc. | 583,357 | $12,636,000 | 0.74% |
Nicholas Investment Partners, LP | 158,704 | $3,438,000 | 0.32% |
SECTORAL ASSET MANAGEMENT INC | 60,000 | $1,300,000 | 0.26% |